A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy

Journal of Urology

Volumn 189, Issue 6, 2013, Pages 2229-2236

  Mulhall, John P ^a   Burnett, Arthur L ^b   Wang, Run ^c   McVary, Kevin T ^d   Moul, Judd W ^e   Bowden, Charles H ^f   Didonato, Karen ^f   Shih, Winnie ^f   Day, Wesley W ^f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e DUKE CANCER INSTITUTE   (United States)

^f Menlo Park and VIVUS   (United States)

Author keywords

clinical trial; erectile dysfunction; phase III; phosphodiesterase 5 inhibitors; prostatectomy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; AVANAFIL; PLACEBO;

ADULT; AGED; ARTICLE; BACKACHE; BILATERAL NERVE SPARING RADICAL PROSTATECTOMY; BRONCHITIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROCARDIOGRAM; ERECTILE DYSFUNCTION; FAINTNESS; FLUSHING; HEADACHE; HEART RATE; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NOSE OBSTRUCTION; PENIS ERECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATECTOMY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERECTILE DYSFUNCTION; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; PROSPECTIVE STUDIES; PROSTATE; PROSTATECTOMY; PYRIMIDINES; REFERENCE VALUES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84877627609     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.11.177     Document Type: Article

References (26)

1. C.C. Carson 3rd, J.S. Hubbard, E. Wallen Erectile dysfunction and treatment of carcinoma of the prostate Curr Urol Rep 6 2005 461
2. T. Siegel, J.W. Moul, M. Spevak The development of erectile dysfunction in men treated for prostate cancer J Urol 165 2001 430
3. J.L. Stanford, Z. Feng, A.S. Hamilton Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study JAMA 283 2000 354
4. A. Gallina, M. Ferrari, N. Suardi Erectile function outcome after bilateral nerve sparing radical prostatectomy: which patients may be left untreated? J Sex Med 9 2012 903
5. D.F. Penson, D. McLerran, Z. Feng 5-Year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study J Urol, suppl. 179 2008 S40
6. Viagra (sildenafil citrate) tablets prescribing information 2010 Pfizer Labs New York, New York
7. Levitra (vardenafil HCL) tablets prescribing information 2011 Bayer HealthCare Pharmaceuticals Wayne, New Jersey
8. Cialis (tadalafil) tablets prescribing information 2011 Eli Lilly and Company Indianapolis, Indiana
9. STENDRA (avanafil) tablets prescribing information 2012 VIVUS, Inc Mountain View, California
10. B.H. Lowentritt, P.T. Scardino, B.J. Miles Sildenafil citrate after radical retropubic prostatectomy J Urol 162 1999 1614
11. G. Brock, A. Nehra, L.I. Lipshultz Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy J Urol 170 2003 1278
12. R. Raina, M.M. Lakin, A. Agarwal Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy Urology 63 2004 960
13. J. Kotera, H. Mochida, H. Inoue Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction J Urol 188 2012 668
14. R. Wang, A.L. Burnett, W.H. Heller Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability J Sex Med 2012 Epub ahead of print
15. M. Allison, T. Grant, M. Obaidi Pharmacokinetics of avanafil, a novel, rapidly absorbed, selective PDE5 inhibitor for the treatment of mild to severe erectile dysfunction J Sex Med 8 suppl. 2011 S466
16. W.J. Hellstrom, M.T. Freier, E.C. Serefoglu A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction BJU Int 111 2013 137
17. I. Goldstein, A.R. McCullough, L.A. Jones A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction J Sex Med 9 2012 1122
18. I. Goldstein, L.A. Jones, L.H. Belkoff Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes Mayo Clin Proc 87 2012 843
19. l. Belkoff, A. McCullough, I. Goldstein An open-label, long-term evaluation of the safety and tolerability of avanafil in males with erectile dysfunction Int J Clin Pract 67 2013 333
20. International Conference on Harmonisation International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use www.ich.org/products/guidelines.html Accessed June 19, 2012
21. World Medical Association General Assembly WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects www.wma.net/en/30publications/10policies/b3/ Accessed September 19, 2012
22. D.K. Montague, J.P. Jarow, G.A. Broderick American Urological Association (AUA) Practice Guidelines: Management of erectile dysfunction ('05/Updated '06). Chapter 1 (Appendix 1-A) and Chapter 2 (Appendix 2-C) www.auanet.org/ content/clinical-practice-guidelines/clinical-guidelines.cfm?sub=ed Accessed September 19, 2012
23. R.C. Rosen, A. Riley, G. Wagner The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction Urology 49 1997 822
24. R. Jaeschke, J. Singer, G.H. Guyatt Measurement of health status. Ascertaining the minimal clinically important difference Control Clin Trials 10 1989 407
25. A.B. Araujo, K.R. Allen, R.C. Rosen Minimal clinically important differences in the vaginal insertion and successful intercourse items of the sexual encounter profile J Sex Med 9 2012 169
26. R.C. Rosen, K.R. Allen, X. Ni Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale Eur Urol 60 2011 1010